Inventprise
US-based Inventprise pioneers in innovative research, delivering crucial vaccines globally.
Founded
2012US-based Inventprise pioneers in innovative research, delivering crucial vaccines globally.
Founded in Redmond, USA, Inventprise is dedicated to pioneering innovative research and delivering crucial vaccines to global populations in need. The company's core mission is to provide life-saving vaccines through cutting-edge scientific insights and novel products. Their lead product, the Pneumococcal Conjugate Vaccine for Pediatrics, utilizes the proprietary Linker Conjugation Platform to offer longer-lasting protection with broader coverage and a better immune response. Inventprise focuses on creating highly immunogenic and broad-spectrum conjugate vaccines using their scalable Hydrazied-PEG-Hydrazide (Hz-PEG-Hz) linker technology.
Inventprise has garnered attention for its impactful contributions to global health, particularly in pediatric vaccine development. The company has completed Phase 2 clinical trials for its lead vaccine candidate, marking a significant milestone in its mission to combat pneumococcal diseases. Notable investors and affiliated individuals include experts in vaccine research and development, though specific names are not disclosed. Overall, Inventprise's achievements underscore its commitment to enhancing public health through advanced vaccine technologies, potentially saving countless lives worldwide.
Companies similar to Inventprise include InvVax, Omniose, Innovac Therapeutics and PaxVax.
Inventprise was founded in 2012.
Inventprise's headquarters is located in Redmond, WA, US.
Inventprise's most recent funding round was for $90M (USD) in November 2021.
As of Nov 10, 2021, Inventprise has disclosed funding of $90M (USD). Undisclosed round amounts are excluded.
Inventprise has 12 employees as of Feb 5, 2024.
PaxVax
